Newamsterdam Pharma CO N.V. (NAMSW) — SC 13D/A Filings

All SC 13D/A filings from Newamsterdam Pharma CO N.V.. Browse 4 SC 13D/A reports with AI-powered summaries and risk analysis.

SC 13D/A Filings (4)

Frazier Life Sciences Amends 13D Filing for NewAmsterdam Pharma — Dec 17, 2024 Risk: medium
Frazier Life Sciences X, L.P. and its affiliates have filed an amendment to their Schedule 13D, reporting a change in beneficial ownership of NewAmsterdam Pharm
Forbion Capital Partners Amends Stake in NewAmsterdam Pharma — Nov 15, 2024 Risk: medium
Forbion Capital Partners, through its affiliated entities Forbion Growth Management B.V., Forbion Growth Opportunities Fund I Cooperatief U.A., Forbion IV Manag
Bain Capital Life Sciences Adjusts Stake in NewAmsterdam Pharma — Mar 1, 2024 Risk: medium
Bain Capital Life Sciences Fund II, L.P. and its affiliates have amended their Schedule 13D filing regarding NewAmsterdam Pharma Co N.V. The filing, dated March
Frazier Life Sciences Affiliates Maintain Stake in NewAmsterdam Pharma — Feb 21, 2024 Risk: low
Frazier Life Sciences X, L.P. and its affiliates, including Frazier Life Sciences Public Fund, L.P. and Frazier Life Sciences XI, L.P., filed an SC 13D/A indica

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX